arrow_back Trending Legislation
Share share

Broader Authority to Recall Unsafe Drugs

This new act expands the authority to recall unsafe drugs, which previously only applied to controlled substances. This means government agencies can now react more quickly to threats from any type of drug, enhancing the safety of pharmaceutical products available to citizens.
Key points
All drugs, not just controlled substances, can now be subject to cease distribution and recall orders.
The authority of officials to issue drug recall orders has been expanded to include the Director of the Center for Biologics Evaluation and Research.
Imported and exported drugs are also subject to the new, broader recall rules, improving the safety of international pharmaceutical trade.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Protecting Americans from Unsafe Drugs Act of 2023
Print number: HR 2500
Sponsor: Rep. Kim, Andy [D-NJ-3]
Process start date: 2023-04-06
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Broader Authority to Recall Unsafe Drugs

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 2500.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-04-06.

What are the main provisions?

Key points include:

  • All drugs, not just controlled substances, can now be subject to cease distribution and recall orders.
  • The authority of officials to issue drug recall orders has been expanded to include the Director of the Center for Biologics Evaluation and Research.
  • Imported and exported drugs are also subject to the new, broader recall rules, improving the safety of international pharmaceutical trade.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Kim, Andy [D-NJ-3].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

Analysis and Potential Impact of HR 2500

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health